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Ever since their identification, interest in the role of transient receptor potential (TRP) channels in health and
disease has steadily increased. Robust evidence has underlined the role of TRP channels expressed in a subset
of primary sensory neurons of the trigeminal ganglion to promote, by neuronal excitation, nociceptive responses,
allodynia and hyperalgesia. In particular, the TRP vanilloid 1 (TRPV1) and the TRP ankyrin 1 (TRPA1) are expressed
in nociceptive neurons, which also express the sensory neuropeptides, tachykinins, and calcitonin gene-related
peptide (CGRP), which mediate neurogenic inflammatory responses. Of interest, CGRP released from the
trigeminovascular network of neurons is currently recognized as a main contributing mechanism of migraine
attack. The ability of TRPA1 to sense and to be activated by an unprecedented series of exogenous and endogenous
reactive molecules has now been extensively documented. Several of the TRPA1 activators are also known as triggers
of migraine attack. Thus, TRP channels, and particularly TRPA1, may be proposed as novel pathways in migraine
pathophysiology and as possible new targets for its treatment.
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TRP channels
The observation that the stimulation of a specific receptor,
and the consequent, associated transient inward current
[1,2] are necessary to vision in Drosophila melanogaster
has been the primal evidence of the transient receptor
potential (TRP) family of channels, which currently
encompasses more than 50 different channels [3]. TRP
channels represent a heterogeneous system oriented
towards environment perception, and participating in
sensing visual, gustatory, olfactive, auditive, mechanical,
thermal, and osmotic stimuli. TRP channels consist of
six transmembrane domains (S1-S6) with both the NH2
and COOH termini localized into the cytosol. The COOH
region is highly conserved among TRPs, whereas the
NH2 region usually contains different numbers of
ankyrin repeats, the 33-residue motifs with a conserved
backbone and variable residues that mediate protein-
protein interactions [4]. The entry of cations through
homo- or heterotetramers occurs via the pore formed
by loops between the S5 and S6 domains. TRPs are* Correspondence: silvia.benemei@unifi.it
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in any medium, provided the original work is pcommonly described as nonselective Ca2+-permeable
channels, however, their Ca2+/Na+ permeability ratio
may vary widely between different members of the TRP
family [5].
TRP channel gating is operated by both the direct
action on the channel of a plethora of exogenous and
endogenous physicochemical stimuli, and changes in
the intracellular machinery, including activation of
G-protein coupled receptor (GPCR) or tyrosine kinase
receptor [6]. In mammals, the TRP family consists of
28 proteins grouped into 6 subfamilies according to
sequence identity, namely TRP canonical (TRPC), TRP
vanilloid (TRPV), TRP melastatin (TRPM), TRP polycystin
(TRPP), TRP mucolipin (TRPML), and TRP ankyrin (TRPA)
[7,8]. The mammalian TRPC subfamily enlists 7 members
(TRPC1-7), activated by the stimulation of GPCR and
receptor tyrosine kinases [9], although TRPC1 seems to be
directly activated by membrane stretch [10]. The TRPM
has 8 members (TRPM1-8), and TRPM8 is activated by
menthol and low temperatures (< 25°C). Of the three
TRPML members, TRPML1 is widely expressed and
has been described as an H+-sensor of endosomes/lyso-
somes, where it probably prevents overacidification
[11]. The TRPP family can be subdivided into PKD1-
like (TRPP1-like) and PKD2-like (TRPP2-like) proteins,s an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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membrane plasma membrane [12]. Various diseases have
been attributed to mutations of TRP channels. However,
only a few TRP channelopathies, commonly known as
“TRPpathies”, have been conclusively identified so far.
TRPpathies include neurological disorders, renal diseases,
and complex skeletal dysplasias [13].
TRPA1 and other thermo-TRPs
Primary sensory neurons express different TRP channels,
including four of the six members of the TRPV subfamily.
TRPV1, TRPV2, TRPV3, and TRPV4 channels sense
warm-hot temperatures and are chemosensors for a
large series of naturally occurring and synthetic ligands.
TRPV1, the receptor of the vanilloid compound capsaicin
(which promoted the labeling of the group with the V),
is responsive to high proton concentrations (pH 5–6)
[14,15], anandamide [16] and various lipid derivatives
[17]. Camphor and hypotonic solutions are non-selective
activators of the TRPV3 and TRPV4, respectively [18,19].
The synthetic compound 4α-phorbol 12,13-didecanoate
(4α-PDD), low pH, citrate, endocannabinoids, and ara-
chidonic acid metabolites may also gate TRPV4 [20,21].
Activators of TRPV2 are not well identified, although
the uricosuric agent probenecid can activate the channel
[22]. Additional TRPs expressed in nociceptors are TRPA1
and TRPM8. Finally, there is also evidence that TRPM3,
rather uniquely activated by pregnenolone sulfate, seems
to be also expressed in primary sensory neurons [23].
A large NH2-terminal domain with 17 predicted ankyrin
repeat domains characterizes TRPA1, the sole member
of the TRPA subfamily. TRPA1, first cloned from human
fetal lung fibroblasts, is widely expressed in mammals,
where it has been found in hair cells, pancreas, heart,
brain, keratinocytes [24], urinary bladder [25], prostate
[26], arteries [27], enterochromaffin cells [28], odonto-
blasts and dental pulp [29,30], synovial fibroblasts [31],
and epithelial and smooth muscle cells of the airways
and lung [32]. A large amount of evidence shows that
TRPA1 plays a key role in the detection of pungent or
irritant compounds, including principles contained in
different spicy foods, such as allyl isothiocyanate (mustard
oil) in horseradish [33], allicin and diallyldisulfide in
garlic [34], and cinnamaldehyde in cinnamon [35]. Gingerol
(in ginger), eugenol (in cloves), methyl salicylate (in
wintergreen), carvacrol (in oregano), thymol (in thyme and
oregano) [36], are also able to gate TRPA1. In addition,
environmental irritants and industry pollutants, such as
acetaldehyde, formalin, hydrogen peroxide, hypochlorite,
isocyanates, ozone, carbon dioxide, ultraviolet light, and
acrolein (a highly reactive α,β-unsatured aldehyde present
in tear gas, cigarette smoke, smoke from burning vegeta-
tion, and vehicle exhaust), have been recognized as TRPA1
activators [37-45]. The dispute regarding the role of TRPA1as a sensor of mechanical stimuli and noxious cold (< 17°C)
remains unresolved [36]. Electrophilic molecules have
been found to activate TRPA1 via a unique mechanism,
mediated by a Michael addition with specific cysteine
and lysine residues identified in both the rat and human
channel [46,47]. Finally, TRPA1-expressing neurons also
express other TRP channels, in particular TRPV1, and, even
more importantly, the sensory neuropeptides substance
P (SP), neurokinin A (NKA), and calcitonin gene-related
peptide (CGRP). SP/NKA and CGRP release from per-
ipheral endings of nociceptors promoted by TRPV1 or
TRPA1 activation produces a series of responses col-
lectively described as neurogenic inflammation [48].
TRPA1, pain and neurogenic inflammation
It is generally recognized that C and Aδ-fibre sensory
neurons convey pain signals, while neurons with larger-
size fibres mediate touch sensation. Thermo-TRPs, which
under normal conditions are expressed in C and Aδ-fibre
neurons, have been proposed to contribute to transmis-
sion and modulation of nociceptive signals. This conclu-
sion originates from empirical observation that TRPV1
or TRPA1 agonists, derived from foods and spices, are
able to cause, in a dose-dependent fashion, a range from
appreciated hot feelings to unpleasant pain sensation,
as in the case of capsaicin, the selective TRPV1 agonist
contained in hot peppers, and piperine, another TRPV1
agonist present in black pepper, or allyl isothiocyanate,
the TRPA1 agonist contained in mustard or wasabi [5,49].
Another finding that enlists thermo-TRPs as major pain
controlling mechanisms is the clinical use of topical (cuta-
neous) capsaicin application that, by defunctionalizing
sensory nerve terminals, alleviates several pain conditions,
including post-herpetic neuralgias or pain associated with
diabetic neuropathy [50].
Generation of deleted mice and, more importantly,
identification and preclinical development of selective
antagonists for thermo-TRPs, have greatly increased our
knowledge of the role of these channels in the regulation
of acute nociceptive responses and the development of
allodynia and hyperalgesia. While TRPV1-deleted mice
exhibit decreased hyperalgesia to elevated temperatures
[51], TRPA1-deletion abrogated the two classical noci-
ceptive phases to formalin [38]. However, gene deletion
may not completely recapitulate the effects of channel
blockade, as compensatory mechanism may counterbalance
the function of the absent gene-protein. Thus, findings
produced by using selective thermo-TRP antagonists
may better unveil the role of these channels in models
of pain diseases.
For detailed information on other thermo-TRPs, the
reader is referred to previous review articles [5-8] whereas
we will focus on the increasing evidence that supports
the role of TRPA1 in models of both inflammatory and
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neuronal discharge [53,54] evoked by complete Freund’s
adjuvant (CFA) and tumour necrosis factor-α (TNFα),
and mechanical hyperalgesia induced by low doses of
monosodium iodoacetate (MIA) [55] are inhibited by
TRPA1 receptor antagonists in rodents. Convergent find-
ings indicate that TRPA1 contributes to carrageenan-
evoked inflammatory hyperalgesia [56,57]. Carrageenan
administration, among a number of lipid derivatives,
notably increases metabolites of 12-lipoxygenases, par-
ticularly hepoxilins A3 (HXA3) and HXB3, whose hyper-
algesic/allodynic effect is abrogated by TRPA1 antagonism
[58]. It has also been found that TRPA1 mediates ongoing
nociception in chronic pancreatitis [59], and that both
TRPV1 and TRPA1 initiate key pathways to transform
acute into chronic inflammation and hyperalgesia in
pancreatitis [60]. The clinical observation that an anti-
oxidant afforded protection in patients with pancreatitis
[61] indirectly supports the role of the oxidative stress
sensor, TRPA1, in this condition.
The underlying mechanisms that from neural tissue
injury produce the chronic allodynia and hyperalgesia
typical of neuropathic pain are largely unknown. How-
ever, recent reports have pointed to the role of TRPA1
in different models of neuropathic pain. Several meta-
bolic pathways in glycolysis or lipid peroxidation pro-
duce methylglyoxal (MG), which appears in the plasma
in diabetic patients as hyperglycemia strongly enhances
MG accumulation. MG has been recently described to
react reversibly with cysteine residues, and probably due
to this property stimulates TRPA1, thus representing a
likely candidate metabolite to promote neuropathic pain
in metabolic disorders [62]. Chemotherapeutic induced
peripheral neuropathy (CIPN) is a scarcely understood
and poorly treated condition, which, characterized by
spontaneous pain, and mechanical and cold allodynia and
hyperalgesia, causes significant discomfort, and often
therapy discontinuation. CIPN may outlast the time
period of chemotherapeutic drug administration for weeks
or months [63].
Alteration of several ion channels has been advocated
to explain this painful condition, but a univocal consensus
has not emerged. Recently, in mouse models of CIPN
produced by a single administration of oxaliplatin, pac-
litaxel or bortezomib, TRPA1 has been shown to play a
major role in the development and maintenance of cold
and mechanical [64-66]. In a therapeutic perspective, it
is of relevance that treatment with a TRPA1 antagonist
just before and shortly after (about 6 hours) the admin-
istration of bortezomib or oxaliplatin totally prevented
the development and maintenance (for 10–15 days) of
mechanical and cold hypersensitivity [66]. This finding
suggests that TRPA1 is key in initiating CIPN and promot-
ing the transition from an acute to a chronic condition.In addition, TRPA1 antagonists could represent novel
therapeutic strategies of CIPN. In this context, it could
be better understood that the unexpected attenuation
by etodolac, a nonsteroidal anti-inflammatory drug of
mechanical allodynia in a mouse model of neuropathic
pain, might be due to its ability to inhibit TRPA1 [67].
In addition, to contribute to mechanical hyperalgesia,
TRPA1 seems to be involved in the development of cold
allodynia [68]. Cold allodynia was reduced in models of
neuropathic (peripheral nerve injury) and inflammatory
(CFA) pain [69,70] or in models of CIPN, which typically
exhibit this type of hypersensitivity [64-66]. Interestingly,
a familial episodic pain syndrome has been attributed
to a gain of function mutation of TRPA1 TRPA1 [71].
Coincidence between TRPA1 and neuropeptide expres-
sion has been suggested [72,73], although evidence for
coexistence of isolectin B4-positive and non-peptidergic
neurons with TRPA1 has also been reported [74,75].
Notwithstanding, exposure of tissues containing either
peripheral or central sensory nerve terminals to TRPA1
agonists invariably results in a calcium-dependent release
of SP/NKA and CGRP. Thus, TRPA1 stimulation has been
proven to increase sensory neuropeptide release from
oesophagus and urinary bladder, meninges, or dorsal
spinal cord [76-78]. The outcome of such a release in
peripheral tissues encompasses the series of responses
commonly referred to as ‘neurogenic inflammation’ [48]
(Figure 1). Although implication in transmission of noci-
ceptive signals has been proposed, the pathophysiological
outcome of the central release of sensory neuropeptides
within the dorsal spinal cord or brain stem is less clear
(Figure 1).
TRPA1, TRPV1, and migraine
One of the first findings that, although indirectly, sug-
gested the role of TRP channels in cluster headache and
migraine was represented by the protective effect of the
topical, desensitizing application of capsaicin to the pa-
tient nasal mucosa [79,80]. Capsaicin treatment couples
the unique ability of the drug to first activate, and,
subsequently, upon repeated administration, desensitize
both the afferent pathway that from channel activation
conveys nociceptive signals, and the ‘efferent’ function
that results in sensory neuropeptide release [48]. Within
the fifth cranial nerve, capsaicin desensitization causes
the defunctionalization of peripheral and possibly central
nerve endings, thus preventing SP/NKA-dependent plasma
protein extravasation within the dura mater, CGRP-
dependent dilatation of meningeal arterioles, and inhib-
ition of afferent nociceptive impulses. Further support
to the contribution of TRPV1 to migraine mechanism
derived from the observation that ethanol, a known
trigger of migraine attacks, activates CGRP release from
sensory neurons, and promotes CGRP-dependent menin-
Figure 1 Schematic representation of the probable mechanisms of the action of antimigraine remedies, either currently used, or
proven effective in clinical trials (gray boxes) or of novel medicines (empty box), regarding their ability to modulate the release of
calcitonin gene related peptide (CGRP) or the activation of its receptor (CGRP-R). (1) Non steroidal antiinflammatory drugs (NSAIDs) block
prostaglandin synthesis and the ensuing nociceptor sensitization and CGRP release evoked by prostaglandin receptor (PG-R) activation. (2)
Triptans, by activating neuronal 5HT1D receptors, inhibit CGRP release. (3) CGRP-R antagonists inhibit the action of CGRP on effector cells. (4)
Antagonists of transient receptor potential channels (TRPs), including TRP ankyrin 1 (TRPA1), block the ability of a series of stimulants (for TRPA1,
cigarette smoke, acrolein, nitric oxide, umbellulone, and others) to release CGRP. All medicines may act at both peripheral and central endings of
trigeminal nociceptors. Receptor/channel activation may trigger/facilitate (+) or inhibit (−) CGRP release.
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for channel activation, a phenomenon that eventually
results in TRPV1 activation [81,82].
TRPV4 is stimulated by hypoosmotic stimuli that cause
plasma membrane stretch and mechanical distension.
Although this effect could, in principle, be implicated
in the throbbing pain often described by migraine patients
during their headache attacks, no evidence has yet been
reported in support of TRPV4 in any model of head pain.
In contrast, a series of observational findings has recently
been obtained regarding a possible association between
TRPA1 and migraine. In this respect, it is of interest
that a number of compounds, recently identified as TRPA1
agonists, including cigarette smoke, ammonium chloride,
formaldehyde, chlorine, garlic and others [34,38,41,78,83]
are known triggers of migraine attacks in susceptible
individuals [84-89].
Nitric oxide (NO) donor drugs, including nitroglycerine,
are known inducers of migraine attacks and have been
extensively used in migraine provocation studies in
humans [90]. Although their pro-migraine action has
been attributed to their intrinsic vasodilatatory action
[91], the temporal mismatch between vasodilatation
and the onset of migraine-like attacks argues against a
close association between the two phenomena. In fact,
at the time of the maximum vasodilatation, a mild to
moderate headache develops both in migraineurs (more)
and in healthy subjects (less), while delayed migraine-like
attacks, present only in migraine patients, are observedonly 5–6 hours after nitroglycerine administration [92,93].
Although not confirmed in vitro [94]. NO may release
CGRP from trigemino-vascular neurons [95]. More
recently, NO has been revealed to target TRPA1 by
nitrosylation of channel cysteine residues [96], that
seem to differ from those targeted by other reactive
molecules [97], and this novel molecular mechanism
could contribute to the nociceptive response evoked by
NO [98]. It is possible that the S-nitrosylation process
[99], produced by NO, contributes to channel sensitization
to eventually (hours after the exposure to NO) amplify
CGRP release by other agents, thus leading to exagger-
ated neurogenic inflammation and potentiation of pain
responses.
The environmental pollution agent, acrolein, is pro-
duced by the combustion of organic material which causes
its accidental inhalation, which, however, occurs also with
cigarette smoking [100]. Several components of cigarette
smoke, such as acrolein, crotonaldehyde [78], acetaldehyde
[37] and nicotine [101], are TRPA1 agonists. Recently,
acrolein application to the rat nasal mucosa has been
shown to produce ipsilateral meningeal vasodilatation
by a TRPA1- and CGRP-dependent mechanism [102],
thus offering a mechanistic explanation for the association
between the exposure to cigarette smoke and migraine
attack appearance or worsening [103,104].
Herbalism has been instrumental for the development
of pharmacology and also to a better understanding of
pathophysiological mechanisms. These principles also
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(California bay laurel) is also known as the ‘headache
tree’ because of the ability of its scent to trigger headache
attacks in susceptible individuals [105]. A case of cluster
headache-like attacks preceded by cold sensations per-
ceived in the ipsilateral nostril following inhalation of
Umbellularia californica scent has recently been described
in a cluster headache patient whose attacks had ceased
10 years before [106]. The irritant monoterpene ketone,
umbellulone, one of the most abundant reactive mole-
cules of Umbellularia californica, was found to activate
the human recombinant and the constitutive rat/mouse
TRPA1 in trigeminal ganglia (TG) neurons, and via this
mechanism to produce nociceptive behaviour and the
release of CGRP from TG or meningeal tissue in rats [77].
In addition, similar to acrolein, umbellulone application
to the rat nasal mucosa evoked ipsilateral TRPA1- and
CGRP-dependent meningeal vasodilatation [77].
Ligustilide, an electrophilic volatile dihydrophthalide of
dietary and medicinal relevance, has been found to
produce a moderate activation of TRPA1, but also to
inhibit allyl isothiocyanate-evoked stimulation of TRPA1
[107]. This newly identified target of ligustilide offers a
novel mechanistic explanation for the use of the compound
in traditional medicine to treat pain diseases, including
headaches. Finally, although several hypotheses have
been advanced, the mechanism of the analgesic action of
acetaminophen (paracetamol) in different pain conditions
is far from clear. The reactive metabolite of acetamino-
phen, N-acetyl-p-benzo-quinoneimine (NAPQI), is able to
activate the TRPA1 channel and thereby evoke a moderate
and reversible neurogenic inflammatory response, which,
in susceptible individuals, may contribute to emphasizing
inflammation in peripheral tissues [76]. However, NAPQI
may also be produced by cytochrome activity within
the spinal cord, and NAPQI action at the spinal level
results in channel desensitization [108]. Inhibition of
central TRPA1 has been advocated as the mechanism,
which may be responsible the hitherto unexplained an-
algesic and possibly antimigraine action of its parent
molecule [108]. Importantly, this novel spinal mechanism
could be of general relevance also for other TRPA1
agonists which share with NAPQI the ability of de-
sensitizing the channel.
A host of endogenous inflammatory mediators possibly
released during migraine attacks can activate and sensitize
peripheral and central sensory neurons, including tri-
geminal neurons. Sensitization of first-order neurons is
involved in the perception of headache throbbing pain
[109], while sensitization of second‐order neurons con-
tributes to cephalic allodynia and muscle tenderness
[110,111]. Recently, it has been shown that innocuous
brush and heat stimuli induce larger activation in the
thalamus of patients who exhibit allodynia during mi-graine, as compared to pain‐free state, and that topical
application of inflammatory molecules on the rat menin-
ges sensitizes thalamic trigeminovascular neurons [112].
Each component of the nociceptive pathways could con-
tribute differently to sensitization of the neural tissues.
TRP channels could be sensitized by different compounds
and via different mechanisms [5,36,66,81,113]. Although
there is no specific information on the role of these chan-
nels to peripheral nociceptor sensitization or central sensi-
tization in migraine, it is possible that TRP channels, and
in particular TRPV1 and TRPA1, contribute to this key
mechanism.Conclusions
The still largely unfinished puzzle of the migraine mech-
anism is being completed by novel unexpected pieces of
information, which compose a clearer picture. The first,
corner of the picture, known for decades, is that cyclo-
oxygenase (namely cyclooxygenase 2) inhibition has a
beneficial effect on migraine attack. The second corner,
predicted by scientists and appreciated by clinicians and
patients, is that targeting 5-HT1 receptors is also highly
effective. The third corner is that a series of clinical trials
show that CGRP antagonists afford a protection similar
to that of triptans. To complete at least the frame, a
fourth corner, which should reconcile the other three in
an intelligible sequence of events, is needed. While pros-
taglandins sensitize nociceptors and eventually promote
CGRP release, triptans inhibit such release, thus produ-
cing an indirect anti-migraine effect, and CGRP antago-
nists abrogate the final common pathway of migraine
mechanism. The pathway, which, sensitized by prosta-
glandins and inhibited by serotonin receptor stimulation,
results in trigeminal neuron activation and the pro-
migraine release of CGRP could represent the fourth
corner of the picture. Emerging information on TRP chan-
nels, and particularly TRPA1, which, targeted by migraine
triggers, contribute, by activating the trigeminal CGRP-
dependent pathway, to the genesis of pain and the accom-
panying symptoms of the attack, seems to be of paramount
importance to solve what still remains the enigma of the
migraine mechanism.
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